Steven Mizell - Merck President
| MRK Stock | USD 125.23 0.14 0.11% |
President
Mr. Steven C. Mizell was appointed Executive Vice President, Chief Human Resources Officer, Human Resources of the Company effective on October 2018. prior to this he was Throughout his career, Mizell has held positions of increasing responsibility across a range of disciplines within the human resources field. Prior to his role at Monsanto, Mizell was senior vice president and chief corporate resources officer for Advance PCS, a large prescription benefit plan administrator. He also was senior vice president and chief human resources and real estate officer for the technology company Zilog, Inc. Mizell is a Board Member of Oshkosh Corporationrationration, a manufacturer of specialty vehicles and access equipment. He earned a BS in Industrial Management from the Georgia Institute of Technology and a MS in Management and Public Policy Analysis from Carnegie Mellon University. since 2018.
| Age | 60 |
| Tenure | 6 years |
| Address | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Latest Insider Transactions
Merck Management Efficiency
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Mark Currie | Ironwood Pharmaceuticals | 63 | |
| Mark Stejbach | Alkermes Plc | 55 | |
| CTodd Nichols | Alkermes Plc | N/A | |
| DavidAlexandre Gros | Neurocrine Biosciences | 43 | |
| Bill Aurora | Neurocrine Biosciences | N/A | |
| Gordon Pugh | Alkermes Plc | 57 | |
| Craig Hopkinson | Alkermes Plc | 49 | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| Michael Landine | Alkermes Plc | 70 | |
| Halley Gilbert | Ironwood Pharmaceuticals | 48 | |
| Robert Janssen | Dynavax Technologies | 70 | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| David Johnson | Dynavax Technologies | 56 | |
| Mark Namchuk | Alkermes Plc | N/A | |
| David Gaffin | Alkermes Plc | 52 | |
| Christopher Wright | Ironwood Pharmaceuticals | N/A | |
| Shane Cooke | Alkermes Plc | 54 | |
| Kelly MacDonald | Ironwood Pharmaceuticals | 34 | |
| Elliot Ehrich | Alkermes Plc | 57 | |
| Rebecca Peterson | Alkermes Plc | 38 | |
| Adrian Hepner | Eagle Pharmaceuticals | 56 | |
Management Performance
| Return On Equity | 0.009 | ||||
| Return On Asset | 0.0264 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scot Ebbinghaus, VP Development | ||
| Rochelle Lazarus, Independent Director | ||
| Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Caroline Litchfield, Chief Financial Officer, Executive Vice President | ||
| Mirian GraddickWeir, Executive Vice President - Human Resources | ||
| Jannie Oosthuizen, Lead - Human Health U.S. | ||
| Jennifer Mauer, VP Communications | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Gregory Lubiniecki, VP Development | ||
| Michael Klobuchar, Executive Vice President Chief Strategy Officer | ||
| Patricia Russo, Independent Director | ||
| David Williams, Executive Vice President Chief Information Chief Information and Digital Officer | ||
| Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing | ||
| Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Robert Kidder, Independent Director | ||
| Thomas Cech, Independent Director | ||
| William Harrison, Lead Independent Director | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Jim Scholefield, Executive Vice President, Chief Information and Digital Officer | ||
| Deepak Khanna, Lead - Human Health International | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Gideon Blumenthal, Vice Affairs | ||
| Adam Schechter, President of Global Human Health and Executive VP | ||
| Risa LavizzoMourey, Independent Director | ||
| Thomas Glocer, Lead Independent Director | ||
| Craig Thompson, Independent Director | ||
| Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Arpa Garay, Lead - Human Health Global Marketing | ||
| Dalton III, Principal Finance | ||
| Christine Seidman, Independent Director | ||
| Wendell Weeks, Independent Director | ||
| Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
| Kathy Warden, Independent Director | ||
| Adele Ambrose, Senior Vice President Chief Communications Officer | ||
| Joseph Romanelli, IR Contact Officer | ||
| Peter Wendell, Independent Director | ||
| John Noseworthy, Independent Director | ||
| Leslie Brun, Lead Independent Director | ||
| Inge Thulin, Independent Director | ||
| Pamela Craig, Independent Director | ||
| Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Chirfi Guindo, Senior Health | ||
| Joerg Koglin, Vice Development | ||
| Stephen Mayo, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Peter Dannenbaum, Vice Relations | ||
| Clark Golestani, CIO and Executive VP | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
| Carlos Represas, Independent Director | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | ||
| Frank Clyburn, Executive Vice President, Chief Commercial Officer | ||
| Robert JD, President Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.009 | ||||
| Return On Asset | 0.0264 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.0008 % | ||||
| Current Valuation | 345.96 B | ||||
| Shares Outstanding | 2.53 B | ||||
| Shares Owned By Insiders | 0.04 % | ||||
| Shares Owned By Institutions | 78.56 % | ||||
| Number Of Shares Shorted | 19.59 M | ||||
| Price To Earning | 18.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.453 | Dividend Share 2.92 | Earnings Share 0.14 | Revenue Per Share 23.695 | Quarterly Revenue Growth 0.058 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.